ArticleBMC biotechnology2025
Whole-exome sequencing of FFPE samples reveals mutations associated with Luminal A breast cancer recurrence.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEarly-stage Luminal A breast cancer generally has a favorable prognosis, yet some patients experience recurrence, presenting a challenge in understanding the underlying genetic factors. This study aimed to identify genetic mutations associated with recurrence in early-stage Luminal A breast cancer patients through whole-exome sequencing (WES).
methodsWe collected formalin-fixed paraffin-embedded samples from 34 patients and divided them into two groups: 17 patients with recurrence within five years post-surgery (recurrence group) and 17 patients with no recurrence for over five years (control group). The extracted DNA went through library preparation and was subjected to WES. Sequencing data went through quality control, alignment, and mutation identification. Functional enrichment analyses were conducted to explore the biological implications of the mutations.
resultsWe generated on average ~ 11 Gb raw sequencing data for each sample and identified 7,066 nonsynonymous mutations. The recurrence group exhibited a higher mutation rate (11.48 mutations/Mb) compared with the control group (9.18 mutations/Mb, p < 0.05). A significant negative correlation was observed between disease-free survival time and the number of mutations (p < 0.05). Eight genes (MICALCL, G6PD, OR8U1, PCLO, OR8U8, ZCCHC18, CPED1, HMCN1) were significantly associated with early recurrence (p < 0.05). Functional enrichment analyses revealed that these genes were involved in pathways like mismatch repair and immune response.
conclusionsThis study identified specific genetic mutations linked to early recurrence in Luminal A breast cancer, highlighting potential biomarkers for predicting patient outcomes and personalizing cancer treatment. Our study also showed that state-of-the-art WES can extract biologically and clinically meaningful mutation signatures from routinely stored FFPE tissues, unlocking archived specimens for large-scale biomarker discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.